[en] Lung cancer remains the first cause of cancer-related death despite many therapeutic innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily practice at late metastatic stages and locally advanced stages after a chemo-radiation. ICI are also emerging in the peri-operative context. However, all patients do not benefit from ICI and even suffer from additional immune side effects. A current challenge remains to identify patients eligible for ICI and benefiting from these drugs. Currently, the prediction of ICI response is only supported by Programmed death-ligand 1 (PD-L1) tumor expression with perfectible results and limitations inherent to tumor-biopsy specimen analysis. Here, we reviewed alternative markers based on liquid biopsy and focused on the most promising biomarkers to modify clinical practice, including non-tumoral blood cell count such as absolute neutrophil counts, platelet to lymphocyte ratio, neutrophil to lymphocyte ratio, and derived neutrophil to lymphocyte ratio. We also discussed soluble-derived immune checkpoint-related products such as sPD-L1, circulating tumor cells (detection, count, and marker expression), and circulating tumor DNA-related products. Finally, we explored perspectives for liquid biopsies in the immune landscape and discussed how they could be implemented into lung cancer management with a potential biological-driven decision.
Disciplines :
Oncology
Author, co-author :
Ancel, Julien; Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France ; Department of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, France
Dormoy, Valérian; Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France
Raby, Béatrice Nawrocki; Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France
Dalstein, Véronique; Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France ; Department of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, France
Durlach, Anne; Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France ; Department of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, France
Dewolf, Maxime; Department of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, France
Gilles, Christine ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Polette, Myriam; Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France ; Department of Biopathology, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, France
Deslée, Gaëtan; Inserm UMR-S1250, P3Cell, University of Reims Champagne-Ardenne, SFR CAP-SANTE, Reims, France ; Department of Respiratory Diseases, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, Reims, France
Language :
English
Title :
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors.
URCA - Université de Reims Champagne-Ardenne INSERM - Institut National de la Santé et de la Recherche Médicale
Funding text :
With financial support from ITMO Cancer of Aviesan within the framework of the 2021-2030 Cancer Control Strategy, on funds administered by Inserm, from the University of Reims Champagne Ardenne (URCA), France and Reims University Hospitals, France. AcknowledgmentsThe research effort associated with this review was funded in part by the Partenariat Hubert Curien-Tournesol. CG is a Senior Associate Researcher from FRS-FNRS (Belgium).
Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2018) 68:394–424. doi: 10.3322/caac.21492
Duma N Santana-Davila R Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc (2019) 94:1623–40. doi: 10.1016/j.mayocp.2019.01.013
Reck M Rabe KF. Precision diagnosis and treatment for advanced non-Small-Cell lung cancer. N Engl J Med (2017) 377:849–61. doi: 10.1056/NEJMra1703413
Korpanty GJ Graham DM Vincent MD Leighl NB. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol (2014) 4:204. doi: 10.3389/fonc.2014.00204
Prelaj A Tay R Ferrara R Chaput N Besse B Califano R. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer (2019) 106:144–59. doi: 10.1016/j.ejca.2018.11.002
Reck M Rodríguez-Abreu D Robinson AG Hui R Csőszi T Fülöp A et al. Pembrolizumab versus chemotherapy for PD-L1-Positive non-Small-Cell lung cancer. N Engl J Med (2016) 375:1823–33. doi: 10.1056/NEJMoa1606774
Sezer A Kilickap S Gümüş M Bondarenko I Özgüroğlu M Gogishvili M et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet (2021) 397:592–604. doi: 10.1016/S0140-6736(21)00228-2
Herbst RS Giaccone G de Marinis F Reinmuth N Vergnenegre A Barrios CH et al. Atezolizumab for first-line treatment of PD-L1–selected patients with NSCLC. N Engl J Med (2020) 383:1328–39. doi: 10.1056/NEJMoa1917346
Allemani C Matsuda T Di Carlo V Harewood R Matz M Nikšić M et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet (2018) 391:1023–75. doi: 10.1016/S0140-6736(17)33326-3
Marrugo-Ramírez J Mir M Samitier J. Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy. Int J Mol Sci (2018) 19:E2877. doi: 10.3390/ijms19102877
Canale M Pasini L Bronte G Delmonte A Cravero P Crinò L et al. Role of liquid biopsy in oncogene-addicted non-small cell lung cancer. Transl Lung Cancer Res (2019) 8:S265–79. doi: 10.21037/tlcr.2019.09.15
Rolfo C Mack P Scagliotti GV Aggarwal C Arcila ME Barlesi F et al. Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer. J Thorac Oncol (2021) 16:1647–62. doi: 10.1016/j.jtho.2021.06.017
Grivennikov SI Greten FR Karin M. Immunity, inflammation, and cancer. Cell (2010) 140:883–99. doi: 10.1016/j.cell.2010.01.025
Pan Y Fu Y Zeng Y Liu X Peng Y Hu C et al. The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer. biomark Res (2022) 10:9. doi: 10.1186/s40364-022-00355-7
Mitsuhashi A Okuma Y. Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. Clin Transl Oncol (2018) 20:966–74. doi: 10.1007/s12094-017-1827-7
Abu Hejleh T Furqan M Ballas Z Clamon G. The clinical significance of soluble PD-1 and PD-L1 in lung cancer. Crit Rev Oncol Hematol (2019) 143:148–52. doi: 10.1016/j.critrevonc.2019.08.009
Qian H Zhang Y Xu J He J Gao W. Progress and application of circulating tumor cells in non-small cell lung cancer. Mol Ther - Oncolytics (2021) 22:72–84. doi: 10.1016/j.omto.2021.05.005
Punekar SR Shum E Grello CM Lau SC Velcheti V. Immunotherapy in non-small cell lung cancer: past, present, and future directions. Front Oncol (2022) 12:877594. doi: 10.3389/fonc.2022.877594
Hiam-Galvez KJ Allen BM Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer (2021) 21:345–59. doi: 10.1038/s41568-021-00347-z
Nakamura K Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol (2020) 17:1–12. doi: 10.1038/s41423-019-0306-1
Lim JU Yoon HK. Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer. Cytokine (2021) 138:155363. doi: 10.1016/j.cyto.2020.155363
Murakami Y Tamiya A Taniguchi Y Adachi Y Enomoto T Azuma K et al. Retrospective analysis of long-term survival factors in patients with advanced non-small cell lung cancer treated with nivolumab. Thorac Cancer (2022) 13:593–601. doi: 10.1111/1759-7714.14303
Sibille A Henket M Corhay JL Alfieri R Louis R Duysinx B. White blood cells in patients treated with programmed cell death-1 inhibitors for non-small cell lung cancer. Lung (2021) 199:549–57. doi: 10.1007/s00408-021-00474-2
Pu D Xu Q Zhou L-Y Zhou Y-W Liu J-Y Ma X-L. Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors. Thorac Cancer (2021) 12:2914–23. doi: 10.1111/1759-7714.14152
Yuan S Xia Y Shen L Ye L Li L Chen L et al. Development of nomograms to predict therapeutic response and prognosis of non-small cell lung cancer patients treated with anti-PD-1 antibody. Cancer Immunol Immunother (2021) 70:533–46. doi: 10.1007/s00262-020-02710-9
Weber R Fleming V Hu X Nagibin V Groth C Altevogt P et al. Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors. Front Immunol (2018) 9:1310. doi: 10.3389/fimmu.2018.01310
Orillion A Hashimoto A Damayanti N Shen L Adelaiye-Ogala R Arisa S et al. Entinostat neutralizes myeloid-derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma. Clin Cancer Res (2017) 23:5187–201. doi: 10.1158/1078-0432.CCR-17-0741
Bronte G Calabrò L Olivieri F Procopio AD Crinò L. The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis. Clin Exp Med (2022). doi: 10.1007/s10238-022-00946-6
Meyer C Cagnon L Costa-Nunes CM Baumgaertner P Montandon N Leyvraz L et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother (2014) 63:247–57. doi: 10.1007/s00262-013-1508-5
Feng J Chen S Li S Wu B Lu J Tan L et al. The association between monocytic myeloid-derived suppressor cells levels and the anti-tumor efficacy of anti-PD-1 therapy in NSCLC patients. Transl Oncol (2020) 13:100865. doi: 10.1016/j.tranon.2020.100865
Koh J Kim Y Lee KY Hur JY Kim MS Kim B et al. MDSC subtypes and CD39 expression on CD8+ T cells predict the efficacy of anti-PD-1 immunotherapy in patients with advanced NSCLC. Eur J Immunol (2020) 50:1810–9. doi: 10.1002/eji.202048534
Bronte G Petracci E De Matteis S Canale M Zampiva I Priano I et al. High levels of circulating monocytic myeloid-derived suppressive-like cells are associated with the primary resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: an exploratory analysis. Front Immunol (2022) 13:866561. doi: 10.3389/fimmu.2022.866561
Kim HR Park S-M Seo S-U Jung I Yoon HI Gabrilovich DI et al. The ratio of peripheral regulatory T cells to lox-1+ polymorphonuclear myeloid-derived suppressor cells predicts the early response to anti-PD-1 therapy in patients with non-small cell lung cancer. Am J Respir Crit Care Med (2019) 199:243–6. doi: 10.1164/rccm.201808-1502LE
Youn J-I Park S-M Park S Kim G Lee H-J Son J et al. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. Sci Rep (2020) 10:9050. doi: 10.1038/s41598-020-65666-x
Coussens LM Werb Z. Inflammation and cancer. Nature (2002) 420:860–7. doi: 10.1038/nature01322
Lin G-N Peng J-W Xiao J Liu D-Y Xia Z-J. Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet. Med Oncol (2014) 31:70. doi: 10.1007/s12032-014-0070-0
Gu X-B Tian T Tian X-J Zhang X-J. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep (2015) 5:12493. doi: 10.1038/srep12493
Gu X Sun S Gao X-S Xiong W Qin S Qi X et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients. Sci Rep (2016) 6:23893. doi: 10.1038/srep23893
Ksienski D Wai ES Alex D Croteau NS Freeman AT Chan A et al. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab. Transl Lung Cancer Res (2021) 10:355–67. doi: 10.21037/tlcr-20-541
Liu N Mao J Tao P Chi H Jia W Dong C. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Med (Baltimore) (2022) 101:e28617. doi: 10.1097/MD.0000000000028617
Hu B Yang X-R Xu Y Sun Y-F Sun C Guo W et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res (2014) 20:6212–22. doi: 10.1158/1078-0432.CCR-14-0442
Yang R Chang Q Meng X Gao N Wang W. Prognostic value of systemic immune-inflammation index in cancer: a meta-analysis. J Cancer (2018) 9:3295–302. doi: 10.7150/jca.25691
Huang W Luo J Wen J Jiang M. The relationship between systemic immune inflammatory index and prognosis of patients with non-small cell lung cancer: a meta-analysis and systematic review. Front Surg (2022) 9:898304. doi: 10.3389/fsurg.2022.898304
Liu J Li S Zhang S Liu Y Ma L Zhu J et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. J Clin Lab Anal (2019) 33:e22964. doi: 10.1002/jcla.22964
Fang Q Yu J Li W Luo J Deng Q Chen B et al. Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD-1 inhibitor therapy. Clin Exp Pharmacol Physiol (2023) 50:178–90. doi: 10.1111/1440-1681.13740
Suh KJ Kim SH Kim YJ Kim M Keam B Kim TM et al. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody. Cancer Immunol Immunother (2018) 67:459–70. doi: 10.1007/s00262-017-2092-x
Li C Wu J Jiang L Zhang L Huang J Tian Y et al. Correction to: the predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study. Cancer Immunol Immunother (2023) 72:795. doi: 10.1007/s00262-022-03294-2
Ju Q Huang T Zhang Y Wu L Geng J Mu X et al. Systemic immune-inflammation index predicts prognosis in patients with different EGFR-mutant lung adenocarcinoma. Med (Baltimore) (2021) 100:e24640. doi: 10.1097/MD.0000000000024640
Li H Wang G Zhang H Song X Cao J Zhang X et al. Prognostic role of the systemic immune-inflammation index in brain metastases from lung adenocarcinoma with different EGFR mutations. Genes Immun (2019) 20:455–61. doi: 10.1038/s41435-018-0050-z
Chen D Qin H Deng G Wang Q Wang H Liu X. Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy. Clin Transl Oncol (2023) 25:226–35. doi: 10.1007/s12094-022-02936-2
Takada K Takamori S Yoneshima Y Tanaka K Okamoto I Shimokawa M et al. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. Lung Cancer (2020) 145:18–26. doi: 10.1016/j.lungcan.2020.04.034
Katayama Y Yamada T Chihara Y Tanaka S Tanimura K Okura N et al. Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients. Sci Rep (2020) 10:17495. doi: 10.1038/s41598-020-74573-0
Sun K Chen S Xu J Li G He Y. The prognostic significance of the prognostic nutritional index in cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol (2014) 140:1537–49. doi: 10.1007/s00432-014-1714-3
Madeddu C Busquets S Donisi C Lai E Pretta A López-Soriano FJ et al. Effect of cancer-related cachexia and associated changes in nutritional status, inflammatory status, and muscle mass on immunotherapy efficacy and survival in patients with advanced non-small cell lung cancer. Cancers (Basel) (2023) 15:1076. doi: 10.3390/cancers15041076
Tanaka S Uchino J Yokoi T Kijima T Goto Y Suga Y et al. Prognostic nutritional index and lung immune prognostic index as prognostic predictors for combination therapies of immune checkpoint inhibitors and cytotoxic anticancer chemotherapy for patients with advanced non-small cell lung cancer. Diagnostics (Basel) (2022) 12:423. doi: 10.3390/diagnostics12020423
Fang Q Yu J Luo J Deng Q Chen B He Y et al. Combination of baseline and variation of prognostic nutritional index enhances the survival predictive value of patients with advanced non-small cell lung cancer treated with programmed cell death protein 1 inhibitor. Clin Med Insights Oncol (2022) 16:11795549221137134. doi: 10.1177/11795549221137134
Liu N Jiang A Zheng X Fu X Zheng H Gao H et al. Prognostic nutritional index identifies risk of early progression and survival outcomes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors. J Cancer (2021) 12:2960–7. doi: 10.7150/jca.55936
Ni L Huang J Ding J Kou J Shao T Li J et al. Prognostic nutritional index predicts response and prognosis in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Nutr (2022) 9:823087. doi: 10.3389/fnut.2022.823087
Mahiat C Bihin B Duplaquet F Stanciu Pop C Dupont M Vander Borght T et al. Systemic Inflammation/Nutritional status scores are prognostic but not predictive in metastatic non-Small-Cell lung cancer treated with first-line immune checkpoint inhibitors. Int J Mol Sci (2023) 24:3618. doi: 10.3390/ijms24043618
Shoji F Takeoka H Kozuma Y Toyokawa G Yamazaki K Ichiki M et al. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer (2019) 136:45–51. doi: 10.1016/j.lungcan.2019.08.006
Zaitsu J Yamashita Y Ishikawa A Saito A Kagimoto A Mimura T et al. Systemic inflammatory score predicts response and prognosis in patients with lung cancer treated with immunotherapy. Anticancer Res (2021) 41:3673–82. doi: 10.21873/anticanres.15158
Sheng J Yang Y-P Ma Y-X Qin T Hu Z-H Hong S-D et al. Low prognostic nutritional index correlates with worse survival in patients with advanced NSCLC following EGFR-TKIs. PloS One (2016) 11:e0147226. doi: 10.1371/journal.pone.0147226
Granot Z Jablonska J. Distinct functions of neutrophil in cancer and its regulation. Mediators Inflammation (2015) 2015:701067. doi: 10.1155/2015/701067
Kaisar-Iluz N Arpinati L Shaul ME Mahroum S Qaisi M Tidhar E et al. The bilateral interplay between cancer immunotherapies and neutrophils’ phenotypes and Sub-populations. Cells (2022) 11:783. doi: 10.3390/cells11050783
Karantanos T Karanika S Seth B Gignac G. The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. Clin Transl Oncol (2019) 21:206–12. doi: 10.1007/s12094-018-1908-2
Diem S Schmid S Krapf M Flatz L Born D Jochum W et al. Neutrophil-to-Lymphocyte ratio (NLR) and platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer (2017) 111:176–81. doi: 10.1016/j.lungcan.2017.07.024
Khunger M Patil PD Khunger A Li M Hu B Rakshit S et al. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients. PloS One (2018) 13:e0197743. doi: 10.1371/journal.pone.0197743
Facchinetti F Veneziani M Buti S Gelsomino F Squadrilli A Bordi P et al. Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab. Immunotherapy (2018) 10:681–94. doi: 10.2217/imt-2017-0175
Patil PD Khunger M Rakshit S Stevenson J Pennell NA Elson P et al. Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab. JCO (2017) 35:11547–7. doi: 10.1200/JCO.2017.35.15_suppl.11547
Park W Kwon D Saravia D Desai A Vargas F El Dinali M et al. Developing a predictive model for clinical outcomes of advanced non-small cell lung cancer patients treated with nivolumab. Clin Lung Cancer (2018) 19:280–288.e4. doi: 10.1016/j.cllc.2017.12.007
Daher S Lawrence YR Dudnik E Hanovich E Urban D Peled N et al. Nivolumab in non-small cell lung cancer: real world long-term survival results and blood-based efficacy biomarkers. Front Oncol (2021) 11:625668. doi: 10.3389/fonc.2021.625668
Soyano AE Dholaria BR Marin-Acevedo JA Diehl NN Hodge D Lou Y. Baseline peripheral blood biomarkers associated with clinical outcome of advanced lung cancer in patients treated with anti-PD-1 antibody. JCO (2017) 35:e20599–9. doi: 10.1200/JCO.2017.35.15_suppl.e20599
Bagley SJ Kothari S Aggarwal C Bauml JM Alley EW Evans TL et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. Lung Cancer (2017) 106:1–7. doi: 10.1016/j.lungcan.2017.01.013
Rogado J de la Maza MDF Pacheco-Barcia V Serra JM Toquero P Vera B et al. P2.02-027 are inflammatory markers predictive of nivolumab efficacy in advanced non-Small-Cell lung cancer (NSCLC)? J Thorac Oncol (2017) 12:S2108–9. doi: 10.1016/j.jtho.2017.09.1205
Shiroyama T Suzuki H Tamiya M Tamiya A Tanaka A Okamoto N et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med (2018) 7:13–20. doi: 10.1002/cam4.1234
Fukui T Okuma Y Nakahara Y Otani S Igawa S Katagiri M et al. Activity of nivolumab and utility of neutrophil-to-Lymphocyte ratio as a predictive biomarker for advanced non-Small-Cell lung cancer: a prospective observational study. Clin Lung Cancer (2019) 20:208–214.e2. doi: 10.1016/j.cllc.2018.04.021
Passiglia F Galvano A Castiglia M Incorvaia L Calò V Listì A et al. Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients. Ther Adv Med Oncol (2019) 11:1758835919839928. doi: 10.1177/1758835919839928
Russo A Franchina T Ricciardi GRR Battaglia A Scimone A Berenato R et al. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel. J Cell Physiol (2018) 233:6337–43. doi: 10.1002/jcp.26609
Takeda T Takeuchi M Saitoh M Takeda S. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer: NLR in NSCLC 4 weeks after nivolumab. Thorac Cancer (2018) 9:1291–9. doi: 10.1111/1759-7714.12838
Amaral SR Casal Moura M Carvalho J Chaves A Jesus E Sousa G. Prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors. Ann Oncol (2019) 30:i3. doi: 10.1093/annonc/mdz027.004
Dusselier M Deluche E Delacourt N Ballouhey J Egenod T Melloni B et al. Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers. PloS One (2019) 14:e0219060. doi: 10.1371/journal.pone.0219060
Ren F Zhao T Liu B Pan L. Neutrophil–lymphocyte ratio (NLR) predicted prognosis for advanced non-small-cell lung cancer (NSCLC) patients who received immune checkpoint blockade (ICB). OTT (2019) 12:4235–44. doi: 10.2147/OTT.S199176
Pavan A Calvetti L Dal Maso A Attili I Del Bianco P Pasello G et al. Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors. Oncologist (2019) 24:1128–36. doi: 10.1634/theoncologist.2018-0563
Banna GL Signorelli D Metro G Galetta D De Toma A Cantale O et al. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. Transl Lung Cancer Res (2020) 9:1533–42. doi: 10.21037/tlcr-19-583
Banna GL Cortellini A Cortinovis DL Tiseo M Aerts JGJV Barbieri F et al. Corrigendum to “The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer”: [ESMO open volume 6, issue 2, April 2021, 100078]. ESMO Open (2021) 6:100137. doi: 10.1016/j.esmoop.2021.100137
Banna GL Tiseo M Cortinovis DL Facchinetti F Aerts JGJV Baldessari C et al. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy. Thorac Cancer (2022) 13:483–8. doi: 10.1111/1759-7714.14256
Peng L Wang Y Liu F Qiu X Zhang X Fang C et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother (2020) 69:1813–22. doi: 10.1007/s00262-020-02585-w
Ayers KL Ma M Debussche G Corrigan D McCafferty J Lee K et al. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. BMC Cancer (2021) 21:441. doi: 10.1186/s12885-021-08194-9
Takeyasu Y Yoshida T Shibaki R Matsumoto Y Goto Y Kanda S et al. Differential efficacy of pembrolizumab according to metastatic sites in patients with PD-L1 strongly positive (TPS ≥ 50%) NSCLC. Clin Lung Cancer (2021) 22:127–133.e3. doi: 10.1016/j.cllc.2020.10.002
Russo A Russano M Franchina T Migliorino MR Aprile G Mansueto G et al. Neutrophil-to-Lymphocyte ratio (NLR), platelet-to-Lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a Large retrospective multicenter study. Adv Ther (2020) 37:1145–55. doi: 10.1007/s12325-020-01229-w
Alessi JV Ricciuti B Alden SL Bertram AA Lin JJ Sakhi M et al. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. J Immunother Cancer (2021) 9:e003536. doi: 10.1136/jitc-2021-003536
Chen S Li R Zhang Z Huang Z Cui P Jia W et al. Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors. Transl Lung Cancer Res (2021) 10:1397–407. doi: 10.21037/tlcr-21-43
Lim JU Kang HS Yeo CD Kim JS Park CK Kim JW et al. Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. J Thorac Dis (2021) 13:2824–32. doi: 10.21037/jtd-20-3416
Jiang M Peng W Pu X Chen B Li J Xu F et al. Peripheral blood biomarkers associated with outcome in non-small cell lung cancer patients treated with nivolumab and durvalumab monotherapy. Front Oncol (2020) 10:913. doi: 10.3389/fonc.2020.00913
Petrova MP Eneva MI Arabadjiev JI Conev NV Dimitrova EG Koynov KD et al. 31015312. Biosci Trends (2020) 14:48–55. doi: 10.5582/bst.2019.01279
Xiong Q Huang Z Xin L Qin B Zhao X Zhang J et al. Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase. Cancer Immunol Immunother (2021) 70:713–20. doi: 10.1007/s00262-020-02706-5
Matsubara T Takamori S Haratake N Toyozawa R Miura N Shimokawa M et al. The impact of immune-inflammation-nutritional parameters on the prognosis of non-small cell lung cancer patients treated with atezolizumab. J Thorac Dis (2020) 12:1520–8. doi: 10.21037/jtd.2020.02.27
Rossi S Toschi L Finocchiaro G Santoro A. Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer. Immunotherapy (2020) 12:715–24. doi: 10.2217/imt-2019-0154
Simonaggio A Elaidi R Fournier L Fabre E Ferrari V Borchiellini D et al. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol Immunother (2020) 69:2513–22. doi: 10.1007/s00262-020-02637-1
Song P Yang D Cui X Wang H Si X Zhang X et al. NLCIPS: non-small cell lung cancer immunotherapy prognosis score. Cancer Manag Res (2020) 12:5975–85. doi: 10.2147/CMAR.S257967
Mezquita L Auclin E Ferrara R Charrier M Remon J Planchard D et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol (2018) 4:351–7. doi: 10.1001/jamaoncol.2017.4771
Seban R-D Assié J-B Giroux-Leprieur E Massiani M-A Soussan M Bonardel G et al. Association of the metabolic score using baseline FDG-PET/CT and dNLR with immunotherapy outcomes in advanced NSCLC patients treated with first-line pembrolizumab. Cancers (Basel) (2020) 12:E2234. doi: 10.3390/cancers12082234
Prelaj A Rebuzzi SE Pizzutilo P Bilancia M Montrone M Pesola F et al. EPSILoN: a prognostic score using clinical and blood biomarkers in advanced non-small-cell lung cancer treated with immunotherapy. Clin Lung Cancer (2020) 21:365–377.e5. doi: 10.1016/j.cllc.2019.11.017
Yang T Hao L Yang X Luo C Wang G Lin Cai C et al. Prognostic value of derived neutrophil-to-lymphocyte ratio (dNLR) in patients with non-small cell lung cancer receiving immune checkpoint inhibitors: a meta-analysis. BMJ Open (2021) 11:e049123. doi: 10.1136/bmjopen-2021-049123
Niu M Liu Y Yi M Jiao D Wu K. Biological characteristics and clinical significance of soluble PD-1/PD-L1 and exosomal PD-L1 in cancer. Front Immunol (2022) 13:827921. doi: 10.3389/fimmu.2022.827921
Bailly C Thuru X Quesnel B. Soluble programmed death ligand-1 (sPD-L1): a pool of circulating proteins implicated in health and diseases. Cancers (Basel) (2021) 13:3034. doi: 10.3390/cancers13123034
Khan M Zhao Z Arooj S Fu Y Liao G. Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol (2020) 11:587460. doi: 10.3389/fimmu.2020.587460
Gong B Kiyotani K Sakata S Nagano S Kumehara S Baba S et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med (2019) 216:982–1000. doi: 10.1084/jem.20180870
Sagawa R Sakata S Gong B Seto Y Takemoto A Takagi S et al. Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation. JCI Insight (2022) 7:e153323. doi: 10.1172/jci.insight.153323
Zamora Atenza C Anguera G Riudavets Melià M Alserawan De Lamo L Sullivan I Barba Joaquin A et al. The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents. Cancer Immunol Immunother (2022) 71:1823–35. doi: 10.1007/s00262-021-03107-y
Murakami S Shibaki R Matsumoto Y Yoshida T Goto Y Kanda S et al. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody. Thorac Cancer (2020) 11:3585–95. doi: 10.1111/1759-7714.13721
Shimada Y Matsubayashi J Kudo Y Maehara S Takeuchi S Hagiwara M et al. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer. Sci Rep (2021) 11:7830. doi: 10.1038/s41598-021-87575-3
Mazzaschi G Minari R Zecca A Cavazzoni A Ferri V Mori C et al. Soluble PD-L1 and circulating CD8+PD-1+ and NK cells enclose a prognostic and predictive immune effector score in immunotherapy treated NSCLC patients. Lung Cancer (2020) 148:1–11. doi: 10.1016/j.lungcan.2020.07.028
Oh SY Kim S Keam B Kim TM Kim D-W Heo DS. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci Rep (2021) 11:19712. doi: 10.1038/s41598-021-99311-y
Okuma Y Wakui H Utsumi H Sagawa Y Hosomi Y Kuwano K et al. Soluble programmed cell death ligand 1 as a novel biomarker for nivolumab therapy for non-small-cell lung cancer. Clin Lung Cancer (2018) 19:410–417.e1. doi: 10.1016/j.cllc.2018.04.014
Ando K Hamada K Watanabe M Ohkuma R Shida M Onoue R et al. Plasma levels of soluble PD-L1 correlate with tumor regression in patients with lung and gastric cancer treated with immune checkpoint inhibitors. Anticancer Res (2019) 39:5195–201. doi: 10.21873/anticanres.13716
Castello A Rossi S Toschi L Mansi L Lopci E. Soluble PD-L1 in NSCLC patients treated with checkpoint inhibitors and its correlation with metabolic parameters. Cancers (Basel) (2020) 12:E1373. doi: 10.3390/cancers12061373
Costantini A Julie C Dumenil C Hélias-Rodzewicz Z Tisserand J Dumoulin J et al. Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. Oncoimmunology (2018) 7:e1452581. doi: 10.1080/2162402X.2018.1452581
Tiako Meyo M Jouinot A Giroux-Leprieur E Fabre E Wislez M Alifano M et al. Predictive value of soluble PD-1, PD-L1, VEGFA, CD40 ligand and CD44 for nivolumab therapy in advanced non-small cell lung cancer: a case-control study. Cancers (Basel) (2020) 12:E473. doi: 10.3390/cancers12020473
Lambert SL Zhang C Guo C Turan T Masica DL Englert S et al. Association of baseline and pharmacodynamic biomarkers with outcomes in patients treated with the PD-1 inhibitor budigalimab. J Immunother (2022) 45:167–79. doi: 10.1097/CJI.0000000000000408
Ohkuma R Ieguchi K Watanabe M Takayanagi D Goshima T Onoue R et al. Increased plasma soluble PD-1 concentration correlates with disease progression in patients with cancer treated with anti-PD-1 antibodies. Biomedicines (2021) 9:1929. doi: 10.3390/biomedicines9121929
Zhang C Fan Y Che X Zhang M Li Z Li C et al. Anti-PD-1 therapy response predicted by the combination of exosomal PD-L1 and CD28. Front Oncol (2020) 10:760. doi: 10.3389/fonc.2020.00760
Yang Q Chen M Gu J Niu K Zhao X Zheng L et al. Novel biomarkers of dynamic blood PD-L1 expression for immune checkpoint inhibitors in advanced non-Small-Cell lung cancer patients. Front Immunol (2021) 12:665133. doi: 10.3389/fimmu.2021.665133
Liao G Zhao Z Qian Y Ling X Chen S Li X et al. Prognostic role of soluble programmed death ligand 1 in non-small cell lung cancer: a systematic review and meta-analysis. Front Oncol (2021) 11:774131. doi: 10.3389/fonc.2021.774131
Cheng Y Wang C Wang Y Dai L. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis. Future Oncol (2022) 18:261–73. doi: 10.2217/fon-2021-0641
Ricciuti B Jones G Severgnini M Alessi JV Recondo G Lawrence M et al. Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). J Immunother Cancer (2021) 9:e001504. doi: 10.1136/jitc-2020-001504
Peng Y Zhang C Rui Z Tang W Xu Y Tao X et al. A comprehensive profiling of soluble immune checkpoints from the sera of patients with non-small cell lung cancer. J Clin Lab Anal (2022) 36:e24224. doi: 10.1002/jcla.24224
Lin D Shen L Luo M Zhang K Li J Yang Q et al. Circulating tumor cells: biology and clinical significance. Sig Transduct Target Ther (2021) 6:404. doi: 10.1038/s41392-021-00817-8
Deng Z Wu S Wang Y Shi D. Circulating tumor cell isolation for cancer diagnosis and prognosis. eBioMedicine (2022) 83:104237. doi: 10.1016/j.ebiom.2022.104237
Jin F Zhu L Shao J Yakoub M Schmitt L Reißfelder C et al. Circulating tumour cells in patients with lung cancer universally indicate poor prognosis. Eur Respir Rev (2022) 31:220151. doi: 10.1183/16000617.0151-2022
Wankhede D Grover S Hofman P. Circulating tumor cells as a predictive biomarker in resectable lung cancer: a systematic review and meta-analysis. Cancers (Basel) (2022) 14:6112. doi: 10.3390/cancers14246112
Vasseur A Kiavue N Bidard F-C Pierga J-Y Cabel L. Clinical utility of circulating tumor cells: an update. Mol Oncol (2021) 15:1647–66. doi: 10.1002/1878-0261.12869
Tamminga M de Wit S Hiltermann TJN Timens W Schuuring E Terstappen LWMM et al. Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. J Immunother Cancer (2019) 7:173. doi: 10.1186/s40425-019-0649-2
Guibert N Delaunay M Lusque A Boubekeur N Rouquette I Clermont E et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer (2018) 120:108–12. doi: 10.1016/j.lungcan.2018.04.001
Alama A Coco S Genova C Rossi G Fontana V Tagliamento M et al. Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab. J Clin Med (2019) 8:E1011. doi: 10.3390/jcm8071011
Park C-K Oh H-J Kim M-S Koh B-G Cho H-J Kim Y-C et al. Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res (2021) 10:2103–17. doi: 10.21037/tlcr-21-100
Mondelo-Macía P García-González J León-Mateos L Anido U Aguín S Abdulkader I et al. Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab. Mol Oncol (2021) 15:2923–40. doi: 10.1002/1878-0261.13094
Dall’Olio FG Gelsomino F Conci N Marcolin L De Giglio A Grilli G et al. PD-L1 expression in circulating tumor cells as a promising prognostic biomarker in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Clin Lung Cancer (2021) 22:423–31. doi: 10.1016/j.cllc.2021.03.005
Dhar M Wong J Che J Matsumoto M Grogan T Elashoff D et al. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Sci Rep (2018) 8:2592. doi: 10.1038/s41598-018-19245-w
Ikeda M Koh Y Teraoka S Sato K Oyanagi J Hayata A et al. Longitudinal evaluation of PD-L1 expression on circulating tumor cells in non-small cell lung cancer patients treated with nivolumab. Cancers (Basel) (2021) 13:2290. doi: 10.3390/cancers13102290
Nicolazzo C Raimondi C Mancini M Caponnetto S Gradilone A Gandini O et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor nivolumab. Sci Rep (2016) 6:31726. doi: 10.1038/srep31726
Bao H Bai T Takata K Yokobori T Ohnaga T Hisada T et al. High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab. Oncol Lett (2018) 15:3061–7. doi: 10.3892/ol.2017.7671
Papadaki MA Sotiriou AI Vasilopoulou C Filika M Aggouraki D Tsoulfas PG et al. Optimization of the enrichment of circulating tumor cells for downstream phenotypic analysis in patients with non-small cell lung cancer treated with anti-PD-1 immunotherapy. Cancers (Basel) (2020) 12:E1556. doi: 10.3390/cancers12061556
Ouyang Y Liu W Zhang N Yang X Li J Long S. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: a systematic review and meta-analysis. Cancer Med (2021) 10:7021–39. doi: 10.1002/cam4.4236
Jiang A-M Zheng H-R Liu N Zhao R Ma Y-Y Bai S-H et al. Assessment of the clinical utility of circulating tumor cells at different time points in predicting prognosis of patients with small cell lung cancer: a meta-analysis. Cancer Control (2021) 28:10732748211050580. doi: 10.1177/10732748211050581
Cristofanilli M Budd GT Ellis MJ Stopeck A Matera J Miller MC et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 351:781–91. doi: 10.1056/NEJMoa040766
Negin BP Cohen SJ. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options Oncol (2010) 11:1–13. doi: 10.1007/s11864-010-0115-3
Resel Folkersma L Olivier Gómez C San José Manso L Veganzones de Castro S Galante Romo I Vidaurreta Lázaro M et al. Immunomagnetic quantification of circulating tumoral cells in patients with prostate cancer: clinical and pathological correlation. Arch Esp Urol (2010) 63:23–31.
Zhang L Zhang X Liu Y Zhang T Wang Z Gu M et al. PD-L1+ aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients. Cancer Lett (2020) 469:355–66. doi: 10.1016/j.canlet.2019.10.041
Hu B Gong Y Wang Y Xie J Cheng J Huang Q. Comprehensive atlas of circulating rare cells detected by SE-iFISH and image scanning platform in patients with various diseases. Front Oncol (2022) 12:821454. doi: 10.3389/fonc.2022.821454
Genna A Vanwynsberghe AM Villard AV Pottier C Ancel J Polette M et al. EMT-associated heterogeneity in circulating tumor cells: sticky friends on the road to metastasis. Cancers (Basel) (2020) 12. doi: 10.3390/cancers12061632
Bonanno L Dal Maso A Pavan A Zulato E Calvetti L Pasello G et al. Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? Br J Cancer (2022) 127:383–93. doi: 10.1038/s41416-022-01777-8
Peng Y Mei W Ma K Zeng C. Circulating tumor DNA and minimal residual disease (MRD) in solid tumors: current horizons and future perspectives. Front Oncol (2021) 11:763790. doi: 10.3389/fonc.2021.763790
Cheng ML Pectasides E Hanna GJ Parsons HA Choudhury AD Oxnard GR. Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions. CA Cancer J Clin (2021) 71:176–90. doi: 10.3322/caac.21650
Thompson JC Carpenter EL Silva BA Rosenstein J Chien AL Quinn K et al. Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy. JCO Precis Oncol (2021) 5:PO.20.00321. doi: 10.1200/PO.20.00321
Chen Y Li X Liu G Chen S Xu M Song L et al. ctDNA concentration, MIKI67 mutations and hyper-progressive disease related gene mutations are prognostic markers for camrelizumab and apatinib combined multiline treatment in advanced NSCLC. Front Oncol (2020) 10:1706. doi: 10.3389/fonc.2020.01706
Hellmann MD Nabet BY Rizvi H Chaudhuri AA Wells DK Dunphy MPS et al. Circulating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLC. Clin Cancer Res (2020) 26:2849–58. doi: 10.1158/1078-0432.CCR-19-3418
Raja R Kuziora M Brohawn PZ Higgs BW Gupta A Dennis PA et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin Cancer Res (2018) 24:6212–22. doi: 10.1158/1078-0432.CCR-18-0386
Anagnostou V Forde PM White JR Niknafs N Hruban C Naidoo J et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res (2019) 79:1214–25. doi: 10.1158/0008-5472.CAN-18-1127
Li L Wang Y Shi W Zhu M Liu Z Luo N et al. Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy. Cancer Med (2019) 8:7669–78. doi: 10.1002/cam4.2632
Chen Y-T Seeruttun SR Wu X-Y Wang Z-X. Maximum somatic allele frequency in combination with blood-based tumor mutational burden to predict the efficacy of atezolizumab in advanced non-small cell lung cancer: a pooled analysis of the randomized POPLAR and OAK studies. Front Oncol (2019) 9:1432. doi: 10.3389/fonc.2019.01432
Goldberg SB Narayan A Kole AJ Decker RH Teysir J Carriero NJ et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin Cancer Res (2018) 24:1872–80. doi: 10.1158/1078-0432.CCR-17-1341
Iijima Y Hirotsu Y Amemiya K Ooka Y Mochizuki H Oyama T et al. Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer. Eur J Cancer (2017) 86:349–57. doi: 10.1016/j.ejca.2017.09.004
Giroux Leprieur E Herbretau G Dumenil C Julie C Giraud V Labrune S et al. Circulating tumor DNA evaluated by next-generation sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer. Oncoimmunology (2018) 7:e1424675. doi: 10.1080/2162402X.2018.1424675
Nicolas G Jones G Beeler JF Plagnol V Morris C Mourlanette J et al. Targeted sequencing of plasma cell-free DNA to predict response to PD1 inhibitors in advanced non-small cell lung cancer. Lung Cancer (2019) 137:1–6. doi: 10.1016/j.lungcan.2019.09.005
Sun Y Duan J Fang W Wang Z Du X Wang X et al. Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC. BMC Med (2021) 19:239. doi: 10.1186/s12916-021-02075-5
Brueckl NF Wirtz RM Reich FPM Veltrup E Zeitler G Meyer C et al. Predictive value of mRNA expression and dynamic changes from immune related biomarkers in liquid biopsies before and after start of pembrolizumab in stage IV non-small cell lung cancer (NSCLC). Transl Lung Cancer Res (2021) 10:4106–19. doi: 10.21037/tlcr-21-587
van der Leest P Hiddinga B Miedema A Aguirre Azpurua ML Rifaela N Ter Elst A et al. Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors. Mol Oncol (2021) 15:2910–22. doi: 10.1002/1878-0261.13090
Wang H Zhou F Qiao M Li X Zhao C Cheng L et al. The role of circulating tumor DNA in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol (2021) 11:671874. doi: 10.3389/fonc.2021.671874
Schumacher TN Schreiber RD. Neoantigens in cancer immunotherapy. Science (2015) 348:69–74. doi: 10.1126/science.aaa4971
Galon J Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discovery (2019) 18:197–218. doi: 10.1038/s41573-018-0007-y
Hellmann MD Ciuleanu T-E Pluzanski A Lee JS Otterson GA Audigier-Valette C et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med (2018) 378:2093–104. doi: 10.1056/NEJMoa1801946
Hellmann MD Callahan MK Awad MM Calvo E Ascierto PA Atmaca A et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell (2018) 33:853–861.e4. doi: 10.1016/j.ccell.2018.04.001
Gandara DR Paul SM Kowanetz M Schleifman E Zou W Li Y et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med (2018) 24:1441–8. doi: 10.1038/s41591-018-0134-3
Wang Z Duan J Cai S Han M Dong H Zhao J et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol (2019) 5:696–702. doi: 10.1001/jamaoncol.2018.7098
Wang Z Duan J Wang G Zhao J Xu J Han J et al. Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for patients with NSCLC treated with PD-(L)1 inhibitors. J Thorac Oncol (2020) 15:556–67. doi: 10.1016/j.jtho.2019.12.001
Ba H Liu L Peng Q Chen J Zhu Y-D. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer (2021) 21:1220. doi: 10.1186/s12885-021-08924-z
Chae YK Davis AA Agte S Pan A Simon NI Iams WT et al. Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer. Oncologist (2019) 24:820–8. doi: 10.1634/theoncologist.2018-0433
Jiang T Chen J Xu X Cheng Y Chen G Pan Y et al. On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. Mol Cancer (2022) 21:4. doi: 10.1186/s12943-021-01479-4
Kim ES Velcheti V Mekhail T Yun C Shagan SM Hu S et al. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 b-F1RST trial. Nat Med (2022) 28:939–45. doi: 10.1038/s41591-022-01754-x
Rizvi NA Cho BC Reinmuth N Lee KH Luft A Ahn M-J et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol (2020) 6:661–74. doi: 10.1001/jamaoncol.2020.0237
Chen X Fang L Zhu Y Bao Z Wang Q Liu R et al. Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients. Cancer Immunol Immunother (2021) 70:3513–24. doi: 10.1007/s00262-021-02943-2
Ma Y Li Q Du Y Cai J Chen W Zhao G et al. Blood tumor mutational burden as a predictive biomarker in patients with advanced non-small cell lung cancer (NSCLC). Front Oncol (2021) 11:640761. doi: 10.3389/fonc.2021.640761
Wang X Ricciuti B Nguyen T Li X Rabin MS Awad MM et al. Association between smoking history and tumor mutation burden in advanced non-small cell lung cancer. Cancer Res (2021) 81:2566–73. doi: 10.1158/0008-5472.CAN-20-3991
Chmielewska I Stencel K Kalinka E Ramlau R Krawczyk P. Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer-clinical trials experience. Cancers (Basel) (2021) 13:5048. doi: 10.3390/cancers13205048
Provencio M Serna-Blasco R Nadal E Insa A García-Campelo MR Casal Rubio J et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-Small-Cell lung cancer (NADIM phase II trial). J Clin Oncol (2022) 40(25):JCO2102660. doi: 10.1200/JCO.21.02660
Meri-Abad M Moreno-Manuel A García SG Calabuig-Fariñas S Pérez RS Herrero CC et al. Clinical and technical insights of tumour mutational burden in non-small cell lung cancer. Crit Rev Oncology/Hematology (2023) 182:103891. doi: 10.1016/j.critrevonc.2022.103891
Lam VK Zhang J. Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer. J Thorac Dis (2019) 11:2208–11. doi: 10.21037/jtd.2019.05.68
Ancel J Perotin J-M Dewolf M Launois C Mulette P Nawrocki-Raby B et al. Hypoxia in lung cancer management: a translational approach. Cancers (Basel) (2021) 13:3421. doi: 10.3390/cancers13143421
Costantini A Takam Kamga P Dumenil C Chinet T Emile J-F Giroux Leprieur E. Plasma biomarkers and immune checkpoint inhibitors in non-small cell lung cancer: new tools for better patient selection? Cancers (Basel) (2019) 11:E1269. doi: 10.3390/cancers11091269
Wang Q He Y Li W Xu X Hu Q Bian Z et al. Soluble immune checkpoint-related proteins in blood are associated with invasion and progression in non-small cell lung cancer. Front Immunol (2022) 13:887916. doi: 10.3389/fimmu.2022.887916
Zhou L Zhang M Li R Xue J Lu Y. Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature. J Cancer Res Clin Oncol (2020) 146:3269–79. doi: 10.1007/s00432-020-03360-1
Pellini B Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non-Small-Cell lung cancer treated with curative intent. J Clin Oncol (2022) 40:567–75. doi: 10.1200/JCO.21.01929
